Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha–based therapy

Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antig...

Full description

Saved in:
Bibliographic Details
Published inJournal of viral hepatitis Vol. 26; no. S1; pp. 32 - 41
Main Authors Li, Ming‐Hui, Yi, Wei, Zhang, Lu, Lu, Yao, Lu, Hui‐Hui, Shen, Ge, Wu, Shu‐Ling, Hao, Hong‐Xiao, Gao, Yuan‐Jiao, Chang, Min, Liu, Ru‐Yu, Hu, Lei‐Ping, Cao, Wei‐Hua, Chen, Qi‐Qi, Li, Jun‐Nan, Wan, Gang, Xie, Yao
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.07.2019
Subjects
Antigens
chronic hepatitis B
functional cure
Hepatitis
Hepatitis B
Hepatitis B e antigen
hepatitis B e antigen negative
Hepatitis B surface antigen
hepatitis B surface antigen loss
Interferon
Patients
chronic hepatitis B
hepatitis B e antigen negative
functional cure
hepatitis B surface antigen loss
interferon
Online AccessGet full text
ISSN1352-0504
1365-2893
1365-2893
DOI10.1111/jvh.13151

Cover

Abstract Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)‐negative CHB patients. In this prospective study, 176 HBeAg‐negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3‐6 months during the 48‐week follow‐up. The sustained functional cure was evaluated. After the 48‐week follow‐up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P = 0.022 and 23.81% vs 9.23%, P = 0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135‐127.151; P = 0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824‐37.881; P = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.
AbstractList Hepatitis B surface antigen ( HB sAg) loss is considered a functional cure in chronic hepatitis B ( CHB ). However, the durability of HB sAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen ( HB eAg)‐negative CHB patients. In this prospective study, 176  HB eAg‐negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus ( HBV ) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3‐6 months during the 48‐week follow‐up. The sustained functional cure was evaluated. After the 48‐week follow‐up, the sustained functional cure rate was 86.63%. The cumulative rates of HB sAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HB sAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HB sAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P  = 0.022 and 23.81% vs 9.23%, P  = 0.014, respectively). Patients with hepatitis B surface antibody ( HB sAb) had higher rate of sustained functional cure than patients achieving HB sAg loss but without HB sAb (89.86% vs 73.53%, P  = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [ OR ] 16.478; 95% confidence interval [ CI ], 2.135‐127.151; P  = 0.007) and high HB sAb levels ( OR 8.312; 95% CI , 1.824‐37.881; P  = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HB sAg clearance and elevated HB sAb levels help to improve functional cure.
Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)‐negative CHB patients. In this prospective study, 176 HBeAg‐negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3‐6 months during the 48‐week follow‐up. The sustained functional cure was evaluated. After the 48‐week follow‐up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P = 0.022 and 23.81% vs 9.23%, P = 0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135‐127.151; P = 0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824‐37.881; P = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.
Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)‐negative CHB patients. In this prospective study, 176 HBeAg‐negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3‐6 months during the 48‐week follow‐up. The sustained functional cure was evaluated. After the 48‐week follow‐up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P = 0.022 and 23.81% vs 9.23%, P = 0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135‐127.151; P = 0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824‐37.881; P = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.
Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)-negative CHB patients. In this prospective study, 176 HBeAg-negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3-6 months during the 48-week follow-up. The sustained functional cure was evaluated. After the 48-week follow-up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P = 0.022 and 23.81% vs 9.23%, P = 0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135-127.151; P = 0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824-37.881; P = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)-negative CHB patients. In this prospective study, 176 HBeAg-negative CHB patients with functional cure were enrolled for 12 weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3 months; liver imaging examinations were performed every 3-6 months during the 48-week follow-up. The sustained functional cure was evaluated. After the 48-week follow-up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment ≥ 12 weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment < 12 weeks (76.19% vs 90.00%, P = 0.022 and 23.81% vs 9.23%, P = 0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P = 0.012). Consolidation treatment ≥ 12 weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135-127.151; P = 0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824-37.881; P = 0.006) were independent predictors of sustained functional cure. Results suggested that 12 weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.
Author Wu, Shu‐Ling
Cao, Wei‐Hua
Yi, Wei
Li, Ming‐Hui
Lu, Hui‐Hui
Gao, Yuan‐Jiao
Chang, Min
Hu, Lei‐Ping
Wan, Gang
Hao, Hong‐Xiao
Chen, Qi‐Qi
Zhang, Lu
Xie, Yao
Shen, Ge
Lu, Yao
Liu, Ru‐Yu
Li, Jun‐Nan
Author_xml – sequence: 1
  givenname: Ming‐Hui
  surname: Li
  fullname: Li, Ming‐Hui
  organization: Capital Medical University
– sequence: 2
  givenname: Wei
  surname: Yi
  fullname: Yi, Wei
  organization: Capital Medical University
– sequence: 3
  givenname: Lu
  surname: Zhang
  fullname: Zhang, Lu
  organization: Capital Medical University
– sequence: 4
  givenname: Yao
  surname: Lu
  fullname: Lu, Yao
  organization: Capital Medical University
– sequence: 5
  givenname: Hui‐Hui
  surname: Lu
  fullname: Lu, Hui‐Hui
  organization: Capital Medical University
– sequence: 6
  givenname: Ge
  surname: Shen
  fullname: Shen, Ge
  organization: Capital Medical University
– sequence: 7
  givenname: Shu‐Ling
  surname: Wu
  fullname: Wu, Shu‐Ling
  organization: Capital Medical University
– sequence: 8
  givenname: Hong‐Xiao
  surname: Hao
  fullname: Hao, Hong‐Xiao
  organization: Capital Medical University
– sequence: 9
  givenname: Yuan‐Jiao
  surname: Gao
  fullname: Gao, Yuan‐Jiao
  organization: Capital Medical University
– sequence: 10
  givenname: Min
  surname: Chang
  fullname: Chang, Min
  organization: Capital Medical University
– sequence: 11
  givenname: Ru‐Yu
  surname: Liu
  fullname: Liu, Ru‐Yu
  organization: Capital Medical University
– sequence: 12
  givenname: Lei‐Ping
  surname: Hu
  fullname: Hu, Lei‐Ping
  organization: Capital Medical University
– sequence: 13
  givenname: Wei‐Hua
  surname: Cao
  fullname: Cao, Wei‐Hua
  organization: Capital Medical University
– sequence: 14
  givenname: Qi‐Qi
  surname: Chen
  fullname: Chen, Qi‐Qi
  organization: Capital Medical University
– sequence: 15
  givenname: Jun‐Nan
  surname: Li
  fullname: Li, Jun‐Nan
  organization: Capital Medical University
– sequence: 16
  givenname: Gang
  surname: Wan
  fullname: Wan, Gang
  organization: Capital Medical University
– sequence: 17
  givenname: Yao
  surname: Xie
  fullname: Xie, Yao
  email: xieyao00120184@sina.com
  organization: Capital Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31380582$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAUhSNURH9gwQsgS2zoIq1_xomzhIpSUCVYAFvLca4nHmXsYDtTza6PgMTD8D59EhxmikQF3ti6_s65V_ccFwfOOyiK5wSfkXzOV5v-jDDCyaPiiLCKl1Q07GB-c1pijheHxXGMK4wJo5w8KQ4ZYQJzQY-Kn58CdFYnHyLyBsUpJmUddMhMTifrnRqQngIg61APo0o22YjeIHAbGPwISLlkl-Dubr87WObvDaCZApciUrq3sLFu-Zc0TsEo_UeJIgSvB1BBuVy9sanPzRIEk-uzrxrGXt3d_mhVzHOlHoIat0-Lx0YNEZ7t75Piy-XbzxdX5fXHd-8vXl-XmnFGStM1hBmKNaXQMl5XnWCiNc2CUSUwaE0azJu24Z2hoq2p0N2iVYw1omuJ6Wp2Urza-Y7Bf5sgJrm2UcMwKAd-ipLSSvCa1rzK6MsH6MpPIS9wR1FeCSwy9WJPTe0aOjkGu1ZhK-8jycD5DtDBxxjASG2TmqNIQdlBEizn0GUOXf4OPStOHyjuTf_F7t1v7ADb_4Pyw9erneIX4EXCsg
CitedBy_id crossref_primary_10_3390_pathogens14010008
crossref_primary_10_1016_j_livres_2020_02_005
crossref_primary_10_1016_S2468_1253_24_00237_1
crossref_primary_10_3389_fimmu_2022_864354
crossref_primary_10_3389_fmicb_2022_960589
crossref_primary_10_1111_apt_17328
crossref_primary_10_3389_fimmu_2022_1116160
crossref_primary_10_1016_j_bjid_2023_103703
crossref_primary_10_1089_vim_2021_0112
crossref_primary_10_1002_jmv_26301
crossref_primary_10_3350_cmh_2024_0780
crossref_primary_10_1111_jvh_13734
crossref_primary_10_1186_s12985_025_02700_2
crossref_primary_10_1111_jvh_13471
crossref_primary_10_3390_jcm11041126
crossref_primary_10_1016_j_virs_2022_03_001
crossref_primary_10_1080_21645515_2022_2161254
crossref_primary_10_1007_s12072_024_10648_8
crossref_primary_10_1016_j_bsheal_2021_05_001
crossref_primary_10_1007_s12250_020_00290_7
crossref_primary_10_1016_j_gendis_2022_03_003
crossref_primary_10_3748_wjg_v30_i44_4725
crossref_primary_10_12677_acm_2024_1461779
crossref_primary_10_4254_wjh_v16_i4_550
crossref_primary_10_1111_liv_14897
crossref_primary_10_1186_s12985_021_01589_x
crossref_primary_10_1186_s12985_024_02344_8
crossref_primary_10_3389_fmed_2024_1483744
crossref_primary_10_3389_fcimb_2023_1120300
crossref_primary_10_3390_jcm12010361
crossref_primary_10_1186_s12985_024_02522_8
crossref_primary_10_12677_ACM_2023_13112604
crossref_primary_10_1016_j_jhep_2022_01_021
crossref_primary_10_1097_SGA_0000000000000697
crossref_primary_10_3389_fimmu_2022_892031
crossref_primary_10_12677_acm_2024_143884
Cites_doi 10.1016/S0140-6736(05)17701-0
10.1002/hep.1840130403
10.1016/S0168-8278(87)80008-9
10.1093/infdis/jir283
10.1111/liv.13006
10.1002/hep.22295
10.1056/NEJMoa043470
10.7326/0003-4819-150-2-200901200-00100
10.1016/j.intimp.2005.06.004
10.1053/j.gastro.2008.05.031
10.1099/vir.0.020552-0
10.1002/hep.28156
10.1111/jvh.12736
10.1046/j.1365-2893.2003.00487.x
10.1016/j.ijid.2016.03.024
10.1016/j.jhep.2014.05.044
10.1007/s12072-014-9571-3
10.1111/jvh.12755
10.1053/j.gastro.2008.07.008
10.1002/hep.21612
10.1002/hep.22945
10.1053/j.gastro.2015.09.043
10.1002/hep.23327
10.1007/s10620-014-3486-7
10.1128/JVI.75.6.2684-2691.2001
10.1126/science.1243462
10.1016/j.cld.2007.08.001
10.1053/j.gastro.2010.04.052
10.1128/JVI.74.9.4165-4173.2000
10.1016/j.jhep.2009.01.016
10.1128/JVI.00933-15
10.1016/j.jhep.2017.03.021
10.1093/infdis/jiv547
10.1172/JCI58847
10.1053/j.gastro.2009.06.054
10.1080/14712598.2018.1518423
10.1007/s12072-015-9675-4
10.1016/j.jhep.2017.09.018
10.1007/s10059-011-1059-6
10.1136/gutjnl-2013-305517
10.1128/JVI.73.1.474-481.1999
10.1016/j.imbio.2014.07.020
10.3851/IMP1497
10.1111/liv.12661
ContentType Journal Article
Copyright 2019 John Wiley & Sons Ltd
2019 John Wiley & Sons Ltd.
Copyright © 2019 John Wiley & Sons Ltd
Copyright_xml – notice: 2019 John Wiley & Sons Ltd
– notice: 2019 John Wiley & Sons Ltd.
– notice: Copyright © 2019 John Wiley & Sons Ltd
DBID AAYXX
CITATION
NPM
7U9
H94
K9.
7X8
DOI 10.1111/jvh.13151
DatabaseName CrossRef
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef

AIDS and Cancer Research Abstracts
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2893
EndPage 41
ExternalDocumentID 31380582
10_1111_jvh_13151
JVH13151
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Beijing Science and Technology Commission
  funderid: D161100002716002
– fundername: Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (DMCDC)
  funderid: XXZ0302
– fundername: Beijing Municipal Science & Technology Commission
  funderid: Z151100004015122
– fundername: Beijing Municipal Administration of Hospitals Clinical Medicine Development for special funding support
  funderid: XMLX 201706
– fundername: National Science and Technology Major Project of China
  funderid: 2017ZX10201201‐001‐006
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3531-fd913f20c22eb3576d838bf9432a80ecc19059b95df28b728cd4ba3398db1fd73
IEDL.DBID DR2
ISSN 1352-0504
1365-2893
IngestDate Fri Jul 11 14:52:46 EDT 2025
Fri Jul 25 08:25:53 EDT 2025
Mon Jul 21 05:37:00 EDT 2025
Tue Jul 01 03:39:48 EDT 2025
Thu Apr 24 22:57:51 EDT 2025
Wed Jan 22 16:39:34 EST 2025
IsPeerReviewed true
IsScholarly true
Issue S1
Keywords chronic hepatitis B
hepatitis B e antigen negative
functional cure
hepatitis B surface antigen loss
interferon
Language English
License 2019 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3531-fd913f20c22eb3576d838bf9432a80ecc19059b95df28b728cd4ba3398db1fd73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 31380582
PQID 2268256808
PQPubID 1086372
PageCount 10
ParticipantIDs proquest_miscellaneous_2268572756
proquest_journals_2268256808
pubmed_primary_31380582
crossref_citationtrail_10_1111_jvh_13151
crossref_primary_10_1111_jvh_13151
wiley_primary_10_1111_jvh_13151_JVH13151
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2019
PublicationDateYYYYMMDD 2019-07-01
PublicationDate_xml – month: 07
  year: 2019
  text: July 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Journal of viral hepatitis
PublicationTitleAlternate J Viral Hepat
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 35
2010; 15
2012; 122
2014; 219
2005; 352
1991; 13
1987; 4
2017; 24
2017; 67
2016; 10
2011; 32
2009; 150
2014; 63
2015; 9
2014; 61
2007; 11
2016; 36
2009; 49
2009; 137
2018; 68
2011; 204
2015; 89
2004; 11
2018; 18
2015; 60
2009; 50
2005; 365
2010; 139
2017; 11
2000; 74
2005; 5
2008; 48
2016; 63
1999; 73
2016; 213
2013
2008; 135
2010; 91
2007; 45
2010; 51
2016; 46
2014; 343
2001; 75
2016; 150
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
Papatheodoridis GV (e_1_2_9_9_1) 2017; 11
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_42_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_21_1
e_1_2_9_46_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_23_1
e_1_2_9_44_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 150
  start-page: 134
  year: 2016
  end-page: 144
  article-title: Combination of tenofovir disoproxil fumarate and peginterferon α‐2a increases loss of hepatitis B surface antigen in patients with chronic Hepatitis B
  publication-title: Gastroenterology
– volume: 11
  start-page: S4
  year: 2017
  end-page: S5
  article-title: Incidence and risk prediction of hepatocellular carcinoma: a retrospective analysis of the S‐collate study
  publication-title: Hepatol Int
– volume: 68
  start-page: 63
  year: 2018
  end-page: 72
  article-title: Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue‐treated patients
  publication-title: J Hepatol
– volume: 135
  start-page: 1192
  year: 2008
  end-page: 1199
  article-title: HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 13
  start-page: 627
  year: 1991
  end-page: 631
  article-title: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study
  publication-title: Hepatology
– volume: 365
  start-page: 123
  year: 2005
  end-page: 129
  article-title: Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomised trial
  publication-title: Lancet
– volume: 4
  start-page: 45
  year: 1987
  end-page: 51
  article-title: Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma
  publication-title: J Hepatol
– volume: 35
  start-page: 130
  year: 2015
  end-page: 139
  article-title: Loss of hepatitis B surface antigen in a real‐life clinical cohort of patients with chronic hepatitis B virus infection
  publication-title: Liver Int
– volume: 204
  start-page: 408
  year: 2011
  end-page: 414
  article-title: Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen‐negative chronic hepatitis B patients
  publication-title: J Infect Dis
– volume: 50
  start-page: 1084
  year: 2009
  end-page: 1092
  article-title: High rates of HBsAg seroconversion in HBeAg‐positive chronic hepatitis B patients responding to interferon: a long‐term follow‐up study
  publication-title: J Hepatol
– volume: 49
  start-page: S156
  year: 2009
  end-page: S165
  article-title: Reactivation of hepatitis B
  publication-title: Hepatology
– volume: 24
  start-page: 12
  issue: suppl 1
  year: 2017
  end-page: 20
  article-title: Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg‐positive chronic hepatitis B: a five‐year observational cohort study
  publication-title: J Viral Hepat
– volume: 36
  start-page: 100
  issue: suppl 1
  year: 2016
  end-page: 104
  article-title: The prognosis and management of inactive HBV carriers
  publication-title: Liver Int
– volume: 343
  start-page: 1221
  year: 2014
  end-page: 1228
  article-title: Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA
  publication-title: Science
– volume: 5
  start-page: 1839
  year: 2005
  end-page: 1852
  article-title: Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers
  publication-title: Int Immunopharmacol
– volume: 10
  start-page: 1
  year: 2016
  end-page: 98
  article-title: Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
  publication-title: Hepatol Int
– volume: 122
  start-page: 529
  year: 2012
  end-page: 537
  article-title: IFN‐alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
  publication-title: J Clin Invest
– volume: 45
  start-page: 1187
  year: 2007
  end-page: 1192
  article-title: HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long‐term follow‐up
  publication-title: Hepatology
– volume: 67
  start-page: 370
  year: 2017
  end-page: 398
  article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
  publication-title: J Hepatol
– volume: 139
  start-page: 483
  year: 2010
  end-page: 490
  article-title: Hepatitis B surface anti‐gen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers
  publication-title: Gastroenterology
– volume: 89
  start-page: 9200
  year: 2015
  end-page: 9212
  article-title: The Interferon‐ inducible protein tetherin inhibits hepatitis B virus virion secretion
  publication-title: J Virol
– volume: 48
  start-page: 88
  year: 2008
  end-page: 98
  article-title: The antiviral drug selected hepatitis B virus rtA181T/sW172/mutant has a dominant negative secretion defect and alters the typical profile of viral rebound
  publication-title: Hepatology
– volume: 137
  start-page: 1289
  year: 2009
  end-page: 1300
  article-title: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection
  publication-title: Gastroenterology
– volume: 219
  start-page: 944
  year: 2014
  end-page: 949
  article-title: Hepatitis B virus e antigen (HBeAg) may have a negative effect on dendritic cell generation
  publication-title: Immunobiology
– volume: 9
  start-page: 9
  year: 2015
  end-page: 16
  article-title: How to achieve immune control in chronic hepatitis B?
  publication-title: Hepatol Int
– volume: 73
  start-page: 474
  year: 1999
  end-page: 481
  article-title: Hepatitis B virus RNA‐binding proteins associated with cytokine‐induced clearance of viral RNA from the liver of transgenic mice
  publication-title: J Virol
– volume: 46
  start-page: 42
  year: 2016
  end-page: 48
  article-title: Impact of HBeAg on the maturation and function of dendritic cells
  publication-title: Int J Infect Dis
– volume: 11
  start-page: 97
  year: 2004
  end-page: 107
  article-title: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
  publication-title: J Viral Hepat
– volume: 15
  start-page: 133
  year: 2010
  end-page: 143
  article-title: Hepatitis B surface antigen seroclearance during chronic HBV infection
  publication-title: Antivir Ther
– volume: 32
  start-page: 167
  year: 2011
  end-page: 172
  article-title: PKR‐dependent mechanisms of interferon‐alpha for inhibiting hepatitis B virus replication
  publication-title: Mol Cells
– volume: 74
  start-page: 4165
  year: 2000
  end-page: 4173
  article-title: Intrahepatic induction of alpha/beta interferon eliminates viral RNA‐containing capsids in hepatitis B virus transgenic mice
  publication-title: J Virol
– volume: 150
  start-page: 104
  year: 2009
  end-page: 110
  article-title: National Institutes of Health consensus development conference statement: management of hepatitis B
  publication-title: Ann Intern Med
– volume: 213
  start-page: 966
  year: 2016
  end-page: 974
  article-title: Peg‐interferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B
  publication-title: J Infect Dis
– volume: 24
  start-page: 1089
  year: 2017
  end-page: 1097
  article-title: Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: a community‐based real‐world study
  publication-title: J Viral Hepat
– volume: 61
  start-page: 777
  year: 2014
  end-page: 784
  article-title: Switching from entecavir to PegIFN alfa‐2a in patients with HBeAg‐positive chronic hepatitis B: a randomised open‐label trial (OSST trial)
  publication-title: J Hepatol
– volume: 63
  start-page: 1325
  year: 2014
  end-page: 1332
  article-title: HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
  publication-title: Gut
– volume: 352
  start-page: 2682
  year: 2005
  end-page: 2695
  article-title: Peginterferon alfa‐2a, lamivudine, and the combination for HBeAg‐positive chronic hepatitis B
  publication-title: N Engl J Med
– volume: 91
  start-page: 2080
  year: 2010
  end-page: 2090
  article-title: Hepatitis B virus polymerase inhibits RIG‐I‐ and Toll‐like receptor 3‐mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3
  publication-title: J Gen Virol
– volume: 63
  start-page: 261
  year: 2016
  end-page: 283
  article-title: AASLD guidelines for treatment of chronic hepatitis B
  publication-title: Hepatology
– volume: 18
  start-page: 1085
  issue: 10
  year: 2018
  end-page: 1094
  article-title: Interferon‐based treatment is superior to nucleos(t)ide analog in reducing HBV‐related hepatocellular carcinoma for chronic hepatitis B patients at high risk
  publication-title: Expert Opin Biol Ther
– volume: 51
  start-page: 422
  year: 2010
  end-page: 430
  article-title: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen‐positive chronic hepatitis B
  publication-title: Hepatology
– volume: 75
  start-page: 2684
  year: 2001
  end-page: 2691
  article-title: Inhibition of hepatitis B virus replication by the interferon‐inducible MxA protein
  publication-title: J Virol
– volume: 135
  start-page: 459
  year: 2008
  end-page: 467
  article-title: Sustained HBeAg and HBsAg loss after long‐term follow‐up of HBeAg‐positive patients treated with peginterferon alpha‐2b
  publication-title: Gastroenterology
– volume: 11
  start-page: 727
  year: 2007
  end-page: 759
  article-title: The immunology of hepatitis B
  publication-title: Clin Liver Dis
– volume: 60
  start-page: 1457
  year: 2015
  end-page: 1464
  article-title: Seven‐year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection
  publication-title: Dig Dis Sci
– year: 2013
– ident: e_1_2_9_20_1
  doi: 10.1016/S0140-6736(05)17701-0
– ident: e_1_2_9_17_1
  doi: 10.1002/hep.1840130403
– ident: e_1_2_9_16_1
  doi: 10.1016/S0168-8278(87)80008-9
– ident: e_1_2_9_18_1
  doi: 10.1093/infdis/jir283
– ident: e_1_2_9_34_1
  doi: 10.1111/liv.13006
– ident: e_1_2_9_42_1
  doi: 10.1002/hep.22295
– ident: e_1_2_9_21_1
  doi: 10.1056/NEJMoa043470
– ident: e_1_2_9_44_1
  doi: 10.7326/0003-4819-150-2-200901200-00100
– ident: e_1_2_9_28_1
  doi: 10.1016/j.intimp.2005.06.004
– ident: e_1_2_9_12_1
  doi: 10.1053/j.gastro.2008.05.031
– volume: 11
  start-page: S4
  year: 2017
  ident: e_1_2_9_9_1
  article-title: Incidence and risk prediction of hepatocellular carcinoma: a retrospective analysis of the S‐collate study
  publication-title: Hepatol Int
– ident: e_1_2_9_25_1
  doi: 10.1099/vir.0.020552-0
– ident: e_1_2_9_3_1
  doi: 10.1002/hep.28156
– ident: e_1_2_9_31_1
  doi: 10.1111/jvh.12736
– ident: e_1_2_9_45_1
  doi: 10.1046/j.1365-2893.2003.00487.x
– ident: e_1_2_9_27_1
  doi: 10.1016/j.ijid.2016.03.024
– ident: e_1_2_9_8_1
  doi: 10.1016/j.jhep.2014.05.044
– ident: e_1_2_9_30_1
  doi: 10.1007/s12072-014-9571-3
– ident: e_1_2_9_5_1
  doi: 10.1111/jvh.12755
– ident: e_1_2_9_15_1
  doi: 10.1053/j.gastro.2008.07.008
– ident: e_1_2_9_14_1
  doi: 10.1002/hep.21612
– ident: e_1_2_9_46_1
  doi: 10.1002/hep.22945
– ident: e_1_2_9_7_1
  doi: 10.1053/j.gastro.2015.09.043
– ident: e_1_2_9_22_1
  doi: 10.1002/hep.23327
– ident: e_1_2_9_23_1
  doi: 10.1007/s10620-014-3486-7
– ident: e_1_2_9_38_1
  doi: 10.1128/JVI.75.6.2684-2691.2001
– ident: e_1_2_9_35_1
  doi: 10.1126/science.1243462
– ident: e_1_2_9_47_1
  doi: 10.1016/j.cld.2007.08.001
– ident: e_1_2_9_33_1
  doi: 10.1053/j.gastro.2010.04.052
– ident: e_1_2_9_37_1
  doi: 10.1128/JVI.74.9.4165-4173.2000
– ident: e_1_2_9_13_1
  doi: 10.1016/j.jhep.2009.01.016
– ident: e_1_2_9_41_1
  doi: 10.1128/JVI.00933-15
– ident: e_1_2_9_2_1
  doi: 10.1016/j.jhep.2017.03.021
– ident: e_1_2_9_10_1
  doi: 10.1093/infdis/jiv547
– ident: e_1_2_9_36_1
  doi: 10.1172/JCI58847
– ident: e_1_2_9_24_1
  doi: 10.1053/j.gastro.2009.06.054
– ident: e_1_2_9_6_1
  doi: 10.1080/14712598.2018.1518423
– ident: e_1_2_9_4_1
  doi: 10.1007/s12072-015-9675-4
– ident: e_1_2_9_32_1
  doi: 10.1016/j.jhep.2017.09.018
– ident: e_1_2_9_40_1
  doi: 10.1007/s10059-011-1059-6
– ident: e_1_2_9_43_1
  doi: 10.1136/gutjnl-2013-305517
– ident: e_1_2_9_11_1
– ident: e_1_2_9_39_1
  doi: 10.1128/JVI.73.1.474-481.1999
– ident: e_1_2_9_26_1
  doi: 10.1016/j.imbio.2014.07.020
– ident: e_1_2_9_29_1
  doi: 10.3851/IMP1497
– ident: e_1_2_9_19_1
  doi: 10.1111/liv.12661
SSID ssj0013251
Score 2.4315236
Snippet Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping...
Hepatitis B surface antigen ( HB sAg) loss is considered a functional cure in chronic hepatitis B ( CHB ). However, the durability of HB sAg loss after...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 32
SubjectTerms Antigens
chronic hepatitis B
functional cure
Hepatitis
Hepatitis B
Hepatitis B e antigen
hepatitis B e antigen negative
Hepatitis B surface antigen
hepatitis B surface antigen loss
Interferon
Patients
Title Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha–based therapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjvh.13151
https://www.ncbi.nlm.nih.gov/pubmed/31380582
https://www.proquest.com/docview/2268256808
https://www.proquest.com/docview/2268572756
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9UwFD-MgcMX_2zqrk6JwwdfemmT5jZlTyqOy2BDxiZ7EErSJN7h6JX2djCf9hGEfRi_zz6JOUlbdp0D8S20SZOSc5LzS875HYA3FpGPwfAzmUgHUBxmVdnERJTTmDFlE6MxUHj_YDI9TvdO-MkK7PSxMIEfYjhwQ83w6zUquFTNTSU_n40TlvjwafTVQoPokN64QeABbHEaxTxOO1Yh78XTt1zei24ZmMv2qt9wdh_Cl36owc_k27hdqHH54w8Wx__8l0fwoDNEybsgOY9hxVTrcC-kprxYh7X97tJ9A359qrGMaXnI3JImhFwZTXBPDEeJpGxrQ04rMjPoob04bch7Yirvj2SImzzk_Ly-_FmZr55onHR0rg1BX06DhxpLTZu2trIcWhKnJ_MSE1ygjBI8OybIc1Fb9xy_6yOGry-vcE_WJMSUXTyB492PRx-mUZfvISqZWwoiq_OEWRqXlDqI74CQFkwom6eMShE7WXPGC89VzrWlQmUU8y4pyVgutEqszthTWK3mldkEIgSfSMOtQ3dZqq2Uaal4OjE6i3WmRDaCt_3MF2VHho45Oc6KARSdzwo_JSPYHqp-Dwwgf6u01YtP0S0CTeEsW4e_MbfJCF4Pr5364p2MrMy8DXV4hhz8I3gWxG7ohSVMxFxQN1gvPHd3X-x9nvrC83-v-gLuO-MvD67HW7C6qFvz0hlYC_XKa9JveIEoOQ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRTwuPMproYBBHLhkldjxxpG48KqW0q0QalEvKLJjm61AWZRsKpVTfwISP4b_01-Cx06iLg8JcYsSO3HkGXu-8cw3AI8tIh-D6WcykQ6gOMyqsomJKKcxY8omRmOi8Gx3Mt1Ptw_4wRo87XNhAj_E4HBDzfDrNSo4OqTPavnRfJywBPOnz2FFb6xf8PIdPXOGwAPc4jSKeZx2vEI-jqfvurob_WZirlqsfsvZugIf-sGGSJNP43apxuXXX3gc__dvrsLlzhYlz4LwXIM1U23A-VCd8ngDLsy6c_fr8ONtjddYmYcsLGlC1pXRBLfF4E0kZVsbcliRucEg7eVhQ54TU_mQJEPc_CHt5-nJt8p89FzjpGN0bQiGcxr0a6x0bdraynLoSZyqLEqscYFiStB9TJDqorbuPr7XJw2fnnzHbVmTkFZ2fAP2t17tvZhGXcmHqGRuNYiszhNmaVxS6lC-w0JaMKFsnjIqRezEzdkvPFc515YKlVEsvaQkY7nQKrE6YzdhvVpU5jYQIfhEGm4dwMtSbaVMS8XTidFZrDMlshE86ae-KDs-dCzL8bkYcNHRvPBTMoJHQ9MvgQTkT402e_kpunWgKZxx6yA4ljcZwcPhsdNgPJaRlVm0oQ3PkIZ_BLeC3A1fYQkTMRfUDdZLz98_X2y_n_qLO__e9AFcnO7Ndoqd17tv7sIlZwvmIRJ5E9aXdWvuOXtrqe57tfoJwgUsUw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5Vrai4FCg_XVrAIA5cskrsOHHEib_VUmhVIYp6QIri2GYrULZKNpXKqY-AxMPwPn0SPHYSdfmREDcrsWNHnrHns2e-AXhsEPloDD8rosICFItZZZrogHIaMiZNpBUGCu_tJ9PDePeIH63A0z4WxvNDDAduqBluvUYFP1HmspKfzsYRizB8ei1OrLKgRfSOXrpC4B5tcRqEPIw7WiHnxtM3Xd6MfrMwlw1Wt-NMrsHHfqze0eTzuF3Icfn1FxrH__yZ67DRWaLkmRedG7Ciq0244nNTnm3C-l53634TfhzUWMa8PGRuSONjrrQiuCn6s0RStrUmxxWZaXTRXhw35DnRlXNI0sTOHpJ-Xpx_q_QnxzROOj7XhqAzp8ZTjaWmTVubohxaEqso8xIzXKCQEjw8Jkh0URv7HL_rQoYvzr_jpqyIDyo7uwWHk1fvX0yDLuFDUDK7FgRGZREzNCwptRjfIiElmJAmixktRGiFzVovPJMZV4YKmVJMvCQLxjKhZGRUym7DajWv9BYQIXhSaG4svEtjZYoiLiWPE63SUKVSpCN40s98XnZs6JiU40s-oKLTWe6mZASPhqonngLkT5V2evHJu1Wgya1pawE4JjcZwcPhtdVfvJQpKj1vfR2eIgn_CO54sRt6YRETIRfUDtYJz9-7z3c_TF3h7r9XfQDrBy8n-dvX-2-24ao1BDPvhrwDq4u61fessbWQ951S_QRPWisL
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors+of+sustained+functional+cure+in+hepatitis+B+envelope+antigen-negative+patients+achieving+hepatitis+B+surface+antigen+seroclearance+with+interferon-alpha-based+therapy&rft.jtitle=Journal+of+viral+hepatitis&rft.au=Li%2C+Ming-Hui&rft.au=Yi%2C+Wei&rft.au=Zhang%2C+Lu&rft.au=Lu%2C+Yao&rft.date=2019-07-01&rft.eissn=1365-2893&rft.volume=26+Suppl+1&rft.spage=32&rft_id=info:doi/10.1111%2Fjvh.13151&rft_id=info%3Apmid%2F31380582&rft.externalDocID=31380582
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-0504&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-0504&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-0504&client=summon